Literature DB >> 17941867

Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes.

B A Brooks1, B Franjic, C R Ban, K Swaraj, D K Yue, D S Celermajer, S M Twigg.   

Abstract

AIM: Diabetic cardiomyopathy is an increasingly recognized entity. The pathogenic factors that may contribute to its development, especially the earliest changes of diastolic dysfunction (DD), have not been clearly defined. Microvessel dysfunction and upregulation of profibrotic growth factors have been described as possible causes. The aim of this study was therefore to determine whether microvascular dysfunction and/or upregulation of the profibrotic connective tissue growth factor (CTGF) are associated with subclinical DD in subjects with type 2 diabetes.
METHODS: Forty subjects with type 2 diabetes and 20 age-matched non-diabetic controls, all of whom had no clinical evidence of ischaemic heart disease, cardiac failure or echo evidence of systolic ventricular dysfunction, were recruited. Microvascular function was measured by laser Doppler velocimetry, with examination of endothelium-dependent increase in blood flow following iontophoresis of acetylcholine (ACh) and endothelium-independent increase in blood flow in response to the nitric oxide donor sodium nitroprusside (SNP). CTGF levels were determined by Western immunoblotting.
RESULTS: DD determined on the basis of traditional echocardiographic criteria was similar in diabetic subjects compared with controls (28 vs. 20%, p = 0.5). Using left ventricular myocardial tissue Doppler-based indices for DD, the E/E' and the E'/A' ratios (where E is the flow related to early ventricular filling and E' and A' are early and late diastolic velocities, respectively) in diabetic subjects revealed evidence of more DD than controls (p = 0.046 and p = 0.007 respectively) . Comparing controls with no DD by conventional echocardiographic criteria (Group I), diabetes and no DD (Group II) and diabetes with DD (Group III), there was a significant trend in reduction of both endothelium-dependent (ACh fold change; p = 0.04) and endothelium-independent (SNP fold change; p = 0.0004) blood flow across the groups. The ACh and SNP responses, however, were not correlated significantly with quartiles of the E/E' ratio or the E'/A' ratio. CTGF plasma levels did not differ across the groups and CTGF did not correlate with parameters of microvascular function.
CONCLUSIONS: This study indicates that while there is a significant association between DD and measures of microvascular function, the relationship between endothelial dysfunction, CTGF and subtle measures of DD is not strong. Other factors are therefore likely to play an important role in the early pathogenesis of subclinical cardiac DD in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941867     DOI: 10.1111/j.1463-1326.2007.00803.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  28 in total

1.  CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells.

Authors:  Xiaoyu Wang; Susan V McLennan; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2011-06-02       Impact factor: 5.782

Review 2.  Effects of exercise training on arterial function in type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  David Montero; Guillaume Walther; Eric Benamo; Antonia Perez-Martin; Agnès Vinet
Journal:  Sports Med       Date:  2013-11       Impact factor: 11.136

Review 3.  Evidence for distinct effects of exercise in different cardiac hypertrophic disorders.

Authors:  Emily J Johnson; Brad P Dieter; Susan A Marsh
Journal:  Life Sci       Date:  2015-01-26       Impact factor: 5.037

Review 4.  Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.

Authors:  Benjamin M Leon; Thomas M Maddox
Journal:  World J Diabetes       Date:  2015-10-10

Review 5.  Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-analysis.

Authors:  Jing Xie; M Kamran Ikram; Mary Frances Cotch; Barbara Klein; Rohit Varma; Jonathan E Shaw; Ronald Klein; Paul Mitchell; Ecosse L Lamoureux; Tien Yin Wong
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

6.  Echocardiographic Parameters of Clinically Normal Geriatric Rhesus Macaques (Macacamulatta).

Authors:  Yu Ueda; Catherine T Gunther-Harrington; Christina L Cruzen; Jeffrey A Roberts; Joshua A Stern
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-07-01       Impact factor: 1.232

Review 7.  Is diabetic cardiomyopathy a specific entity?

Authors:  Mitja Letonja; Danijel Petrovič
Journal:  World J Cardiol       Date:  2014-01-26

8.  Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress.

Authors:  Gábor Koncsos; Zoltán V Varga; Tamás Baranyai; Kerstin Boengler; Susanne Rohrbach; Ling Li; Klaus-Dieter Schlüter; Rolf Schreckenberg; Tamás Radovits; Attila Oláh; Csaba Mátyás; Árpád Lux; Mahmoud Al-Khrasani; Tímea Komlódi; Nóra Bukosza; Domokos Máthé; László Deres; Monika Barteková; Tomáš Rajtík; Adriana Adameová; Krisztián Szigeti; Péter Hamar; Zsuzsanna Helyes; László Tretter; Pál Pacher; Béla Merkely; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-08-12       Impact factor: 4.733

9.  The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota.

Authors:  Sanjay Dandamudi; Joshua Slusser; Douglas W Mahoney; Margaret M Redfield; Richard J Rodeheffer; Horng H Chen
Journal:  J Card Fail       Date:  2014-02-24       Impact factor: 5.712

Review 10.  Vascular smooth muscle function in type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  David Montero; Guillaume Walther; Antonia Pérez-Martin; Nestor Vicente-Salar; Enrique Roche; Agnès Vinet
Journal:  Diabetologia       Date:  2013-07-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.